TITLE

Bacterial Lipoproteins Differentially Regulate Human Primary and Memory CD4+ T and B Cell Responses to Pneumococcal Protein Antigens through Toll-Like Receptor 2

AUTHOR(S)
Qibo Zhang; Bagrade, Linda; Clarke, Ed; Paton, James C.; Nunez, Desmond A.; Finn, Adam
PUB. DATE
June 2010
SOURCE
Journal of Infectious Diseases;6/1/2010, Vol. 201 Issue 11, p1753
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Bacterial lipoproteins (BLPs) are expressed across a range of bacteria and are able to activate Toll-like receptor 2 (TLR-2). BLPs enhance immune responses in naive individuals and have therefore been tested as candidate vaccine adjuvants. It is not known whether BLPs affect any preexisting immunity (eg, memory cell response in primed individuals). Colonization with pneumococcus (PNC), which primes for memory cell response, is common in young children. Methods. We studied effects of BLPs on memory and primary B and CD4+ T cell responses to pneumococcal proteins using adenoidal cells from children. Results. Although BLPs enhanced the primary antibody responses seen in some children with no detectable nasal PNC, BLPs unexpectedly reduced the memory antibody responses in children with positive nasal culture results. Likewise, BLPs augmented the naive but inhibited the memory antigen-driven CD4+ T cell response. The downregulation of the memory responses was associated with increases in interleukin 10 and inducible costimulatory molecule expression, as well as a decrease in CD28 expression in memory CD4+ T cells; all were blocked by anti-TLR2 and anti-B7h antibodies. Augmentation of naive CD4+ T cell proliferation was blocked by anti-B7.2. Conclusion. Differential regulation of primary and memory responses by BLPs through TLR2 may have important implications for therapeutic and vaccination strategies against bacterial infection.
ACCESSION #
51208298

 

Related Articles

  • Are Anticapsular Antibodies the Primary Mechanism of Protection against Invasive Pneumococcal Disease? Lipsitch, Marc; Whitney, Cynthia G.; Zell, Elizabeth; Kaijalainen, Tarja; Dagan, Ron; Malley, Richard // PLoS Medicine;Jan2005, Vol. 2 Issue 1, p62 

    Background Antibody to capsular polysaccharide has been the basis of several vaccines that offer protection against invasive disease from Streptococcus pneumoniae. The success of such vaccines has led to the inference that natural protection against invasive pneumococcal disease is largely...

  • Pneumococcal Vaccination of Elderly Adults: New Paradigms for Protection. Jackson, Lisa A.; Janoff, Edward N. // Clinical Infectious Diseases;11/15/2008, Vol. 47 Issue 10, p1328 

    Pneumococcal polysaccharide vaccine has been licensed for use in the United States for >30 years, and two-thirds of the elderly population in the United States have received this vaccine. Observational studies have demonstrated that pneumococcal polysaccharide vaccine reduces the risk of...

  • Pneumococcal Conjugate Vaccine, Polysaccharide Vaccine, or Both for Adults? We're Not There Yet. O'Brien, Katherine L. // Clinical Infectious Diseases;11/1/2009, Vol. 49 Issue 9, p1326 

    The article presents the author's comments on the study which gives comparative immunogenicity data on the use of pneumococcal conjugate vaccine (PCV) and polysaccharide vaccine (PPV23), in combination or alone, in adults. He argues that large immunoglobulin G (IgG) concentrations were found in...

  • The distinct effects of three tandem repeats of C3d in the immune responses against tumor-associated antigen hCGβ by DNA immunization. Qing Dong Guan; Ying Wang; Yi Wei Chu; Li Xin Wang; Jing Ni; Qiang Guo; Si Dong Xiong // Cancer Immunology, Immunotherapy;Jun2007, Vol. 56 Issue 6, p875 

    Several examples have shown that C3d3, when fused to a corresponding antigen, had a strong adjuvant effect on certain specific antibody production. In a previous study, we attempted to prove that this was the case of the human chorionic gonadotrophin β chain (hCGβ)-induced immunity...

  • Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination. Westerink, M. A. Julie; Schroeder Jr., Harry W.; Nahm, Moon H. // Aging & Disease;Feb2012, Vol. 3 Issue 1, p51 

    Streptococcus pneumoniae is a significant human pathogen and currently available pneumococcal vaccines are designed to elicit anti-capsule antibodies. The 23-valent polysaccharide vaccine has been used in older adults for many years whereas 7-, 10-, and 13-valent pneumococcal conjugate vaccines...

  • New PCV7 recommendations.  // Infectious Diseases in Children;May2008, Vol. 21 Issue 5, p13 

    The article reports on the updated recommendations for the use of the 7-valent pneumococcal conjugate vaccine in children aged 24 to 59 months. The Pneumococcal Vaccines Work Group presented data regarding the safety and immunogenicity of PCV7 among children in this age group at the Advisory...

  • Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. Rozenbaum, Mark H.; Sanders, Elisabeth A. M.; van Hoek, Albert Jan; Jansen, Angelique G. S. C.; van der Ende, Arie; van der Dobbelsteen, Germie; Rodenburg, Gerwin D.; Hak, Eelko; Postma, Maarten J. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;6/19/2010, Vol. 340 Issue 7760, p1347 

    The article offers information on a study which investigated the compared cost effectiveness of seven valent of pneumococcal vaccines within the Dutch national immunization program. The valent pneumococcal conjugated vaccines (PCV) considered in the study were the PCV-7, PCV-10 and PCV-13. Study...

  • Rwanda launches vaccine drive against pneumococcal disease in under 5s. Moszynski, Peter // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/2/2009, Vol. 338 Issue 7702, p1036 

    The article reports on a 2009 decision from the government of Rwanda to launch a national immunization program to combat pneumococcal disease, which is the leading killer of children under the age of five worldwide and is preventable with vaccination. The disease causes life threatening...

  • Update on Pneumococcal Conjugate Vaccine Shortage. Morantz, Carrie; Torrey, Brian // American Family Physician;9/1/2004, Vol. 70 Issue 5, p985 

    Presents an update on pneumococcal conjugate vaccine shortage in the U.S., as of September 2004. Cause of the shortage; Recommendations given to physicians concerning the vaccination of children; Advantage of catch-up vaccination.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics